恶性血液病患者侵袭性真菌病防治策略

[1]	Zhang P,Jiang EL,Yang DL,et al.Risk factors and prognosis of invasive fungal infections in allogeneic stem cell transplantation recipients:a single-institution experience[J].Transpl Infect Dis,2010,12:316-321.
[2]	Pagano L,Caira M,Candoni A,et al.The epidemiology of fungal infections in patients with hematologic malignancies:the SEIFEM-2004 study[J].Haematologica,2006,91:1068-1075.
[3]	Kurosawa M,Yonezumi M,Hashino S,et al.Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies[J].Int J Hematol,2012,96:748-757.
[4]	Li Y,Xu W,Jiang Z,et al.Neutropenia and invasive fungal infection in patients with hematological malignancies treated with chemotherapy:a multicenter,prospective,non-interventional study in China[J].Tumor Biol,2014,35:5869-5876.
[5]	Tacke D,Buchheidt D,Karthaus M,et al.Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies.2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology[J].Ann Hematol,2014,93:1449-1456.
[6]	Girmenia C,Barosi G,Piciocchi A,et al.Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation:revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO)[J].Biol Blood Marrow Transplant,2014,20:1080-1088.
[7]	Cornely OA,Maertens J,Winston DJ,et al.Posaconazole vs.fluconazole or itraconazole prophylaxis in patients with neutropenia[J].N Engl J Med,2007,356:348-359.
[8]	Ullmann AJ,Lipton JH,Vesole DH,et al.Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease[J].N Engl J Med,2007,356:335-347.
[9]	Pechlivanoglou P,Le HH,Daenen S,et al.Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies:a systematic review[J].J Antimicrob Chemother,2014,69:1-11.
[10]	Vehreschild MJ,von Bergwelt-Baildon M,Tran L,et al.Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation:a 6-yr analysis from the cologne cohort for neutropenic patients[J].Eur J Haematol,2014,93:400-406.
[11]	Goldberg E,Gafter-Gvili A,Robenshtok E,et al.Empirical antifungal therapy for patients with neutropenia and persistent fever:Systematic review and meta-analysis[J].Eur J Cancer,2008,44:2192-2203.
[12]	王建祥.血液病诊疗规范[M].北京:中国协和医科大学出版社,2014:323-332.
[13]	Drgona L,Khachatryan A,Stephens J,et al.Clinical and economic burden of invasive fungal diseases in Europe:focus on pre-emptive and empirical treatment of Aspergillus and Candida species[J].Eur J Clin Microbiol Infect Dis.2014,33:7-21.
[14]	Caillot D,Thiébaut A,Herbrecht R,et al.Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies:a randomized pilot study (Combistrat trial)[J].Cancer,2007,110:2740-2746.
[15]	Gupta AO,Singh N.Immune reconstitution syndrome and fungal infections[J].Curr Opin Infect Dis,2011,24:527-533.
[16]	Todeschini G,Murari C,Bonesi R,et al.Invasive aspergillosis in neutropenic patients:rapid neutrophil recovery is a risk factor for severe pulmonary complications[J].Eur J Clin Invest,1999,29:453-457.
[17]	Caillot D,Latrabe V,Thiébaut A,et al.Computer tomography in pulmonary invasive aspergillosis in hematological patients with neutropenia:an useful tool for diagnosis and assessment of outcome in clinical trials[J].Eur J Radiol,2010,74:e172-e175.
[18]	Miceli MH,Maertens J,Buvé K,et al.Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia:Proof of principle,description,and clinical and research implications[J].Cancer,2007,110:112-120.